الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 112 |  |  |
| | | from | 112 | | |
Abstract
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. According to recent estimates, more than 185 million people around the world have been infected with HCV, of whom 350 000 die each year. The introduction of DAAs has advanced the treatment of HCV with high SVR rates and few side effects. Fibrosis regression was approved by invasive and non-invasive methods after viral eradication by IFN based and IFN free regimens. Our study of 150 patients with HCV related cirrhosis, all enrolled patients were compensated cirrhotic patients, using different treatment regimens at Unit of National Committee for Control of Viral Hepatitis in El - Fayoum General Hospital. All patients were screened by EGD and ultrasonography for signs of portal hypertension and were followed during and after treatment.
1. The studied patients were 61 males (40.7%) and 89 females (59.3%) with age ranged from 30 to 80 years old and an average age of 56.81 ±8.9 out of the studied cases; two patients died during the follow-up.
2. Regarding endoscopic signs of portal hypertension, our study showed that the prevalence of gastroesophageal varices among HCV related compensated cirrhotic (Child A) studied patients was 48%.
3. Regarding relation between varices incidence and patients’ (Age, FIB-4, platelet count and spleen size and MELD, treatment experience), our study showed that age and FIB-4 were significantly higher in patients with varices rather than those without varices and no significant association between MELD score and treatment experience with varices incidence.
4. Regarding gastric varices, among patients with varices, seven patients (9.5%) in our study had gastric varices at screening EGD. Regarding the type of the gastric varices, six patients (85.7%) had IGV-1 and one patient (14.3%) had GOV-1. Regarding association with esophageal varices, five patients (71.4%) had both gastric and esophageal varices and two patients had gastric varices alone. Regarding predictors of variceal bleeding, six patients (85.7%) had small varices and one patient had large varix (14.3%) and all varices did not show any red color signs.
5. Regarding progression of varices, variceal size was progressed in 2 patients (3.7%) in a median follow up period of 9 months, one patient (1.9%) developed de novo variceal red color signs and new varices was detected in 3 patients (2.3%) in a median follow up period of 8 months.
6. The prevalence of PHG in our study was 90.7% and regarding progression of PHG, 131 patients were followed, 5 (3.8%) of them showed regression of their PHG severity and one patient (0.8%) progressed in PHG severity and none of the patient developed de novo appearance of PHG and without significant change in PHG incidence before and after treatment.
7. There were no significant changes between sonographic changes of portal hypertension before and after treatment.
8. Regarding non-invasive markers of fibrosis, statistical analysis of our data showed that FIIB-4 decline significantly at week 24 versus baseline values.
9. Our study results showed that there was significant decline in liver enzymes (ALT and AST), INR and significant increase in platelet count before and after treatment with no significant changes in bilirubin and albumin.
10. Regarding the efficacy of DAA, 98% of our patients achieved SVR after 1st regimen administered.